IDH1 and central nervous system cancer: In this review, we summarize the frequency and role of IDH1 and IDH2 mutations in gliomas and myeloid neoplasms, the latter with an emphasis on AML, and the association of these mutations with clinical, morphologic, cytogenetic, and molecular characteristics.